With OA therapeutics, there’s disease, and then there’s illness. Any disease modifying effect that might be there can get drowned out by fibromyalgia... Data on lorecivivint in Marc Hochberg’s anabolic DMOAD overview SP0013 #EULAR2019 @RheumNow https://t.co/GALk9hs8KB